PubMed

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR.

Ann Intern Med. 2006 Mar 21;144(6):397-406.PMID: 16549852 [PubMed - indexed for MEDLINE]Related articlesFree article

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI.

J Clin Oncol. 1998 Mar;16(3):979-85.PMID: 9508180 [PubMed - indexed for MEDLINE]Related articles

Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.

Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI.

Cancer J Sci Am. 2000 Jan-Feb;6(1):13-20.PMID: 10696733 [PubMed - indexed for MEDLINE]Related articles

Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.

[No authors listed]

Ann Intern Med. 2006 Mar 21;144(6):I40. No abstract available. PMID: 16549849 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.

Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM.

JAMA. 2006 May 24;295(20):2374-84.PMID: 16720823 [PubMed - indexed for MEDLINE]Related articlesFree article

Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.

Schrag D, Kuntz KM, Garber JE, Weeks JC.

JAMA. 2000 Feb 2;283(5):617-24.PMID: 10665701 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.

Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI.

J Clin Oncol. 2002 May 15;20(10):2520-9.PMID: 12011131 [PubMed - indexed for MEDLINE]Related articles

Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.

Norum J, Hagen AI, Maehle L, Apold J, Burn J, Møller P.

Eur J Cancer. 2008 May;44(7):963-71. Epub 2008 Mar 24.PMID: 18362067 [PubMed - indexed for MEDLINE]Related articles

Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.

van Roosmalen MS, Verhoef LC, Stalmeier PF, Hoogerbrugge N, van Daal WA.

J Clin Oncol. 2002 Apr 15;20(8):2092-100.PMID: 11956270 [PubMed - indexed for MEDLINE]Related articles

Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.

Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.

Clin Breast Cancer. 2007 Dec;7(11):875-82.PMID: 18269778 [PubMed - indexed for MEDLINE]Related articles

Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.

Schrag D, Kuntz KM, Garber JE, Weeks JC.

N Engl J Med. 1997 May 15;336(20):1465-71. Erratum in: N Engl J Med 1997 Aug 7;337(6):434. PMID: 9148160 [PubMed - indexed for MEDLINE]Related articles

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2008 May 1;122(9):2017-22.PMID: 18196574 [PubMed - indexed for MEDLINE]Related articles

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

JAMA. 2006 Jul 12;296(2):185-92.PMID: 16835424 [PubMed - indexed for MEDLINE]Related articlesFree article

Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2.

Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI.

J Clin Oncol. 1999 Feb;17(2):494-500.PMID: 10080590 [PubMed - indexed for MEDLINE]Related articles

Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.

Calderon-Margalit R, Paltiel O.

Int J Cancer. 2004 Nov 10;112(3):357-64. Review.PMID: 15382059 [PubMed - indexed for MEDLINE]Related articles

Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, Dukel L, Devilee P, van den Ouweland AM, van Geel AN, Klijn JG.

Lancet. 2000 Jun 10;355(9220):2015-20.PMID: 10885351 [PubMed - indexed for MEDLINE]Related articles

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.PMID: 12721241 [PubMed - indexed for MEDLINE]Related articles

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.PMID: 17109443 [PubMed - indexed for MEDLINE]Related articlesFree article

Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.

Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.

Gynecol Oncol. 2005 May;97(2):457-67.PMID: 15863145 [PubMed - indexed for MEDLINE]Related articles

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR.

J Clin Oncol. 2008 Mar 10;26(8):1331-7. Epub 2008 Feb 11.PMID: 18268356 [PubMed - indexed for MEDLINE]Related articles